The human insulin market is predicted to be valued at US$20.4 Bn in 2026 and is projected to reach US$28.6 Bn by 2033, growing at a CAGR of 4.9% in the forecast period. The growth is steady rather than dramatic. It is shaped by a large diabetes population, a highly competitive biosimilar supply base, and a delivery experience that is becoming more connected.
A Growing Diabetes Population is Keeping Demand for Human Insulin Steady
The number of adults living with diabetes is expected to rise from an estimated 537 million in 2021 to 783 million by 2045. Most of them live in low- and middle-income countries where treatment budgets are limited. In these settings, human insulin remains the practical choice because it costs far less than newer analogues and is listed on national essential medicines programs. As screening widens, more patients are diagnosed and started on therapy, which turns into steady prescription volumes.
Short-acting human insulin shows how strong this pull is. It held a share of about 41% in terms of product type in 2025, supported by its place on the World Health Organization (WHO) Essential Medicines List and its cost advantage over rapid-acting analogues. Premixed human insulin is the fastest-growing product type, since a fixed combination keeps dosing simple in primary care clinics that manage type 2 diabetes.
Supply security now matters as much as price. In May 2026, Aspen Pharmacare received approval from the South African Health Products Regulatory Authority to release the first commercial batches of human insulin made for sale in South Africa, under its agreement with Novo Nordisk. The insulin is put into vials at Aspen’s Gqeberha facility, which gives African health programs a reliable source of supply. For manufacturers, this shows that local production partnerships can be a practical route into public-sector demand.
Biosimilar Competition is Lowering Entry Barriers and Widening Access
Manufacturers in India and China, including Biocon, Wockhardt, Tonghua Dongbao, and Gan & Lee, have built scale at price points that suit government tenders. This is widening treatment access across emerging economies. At the same time, it is testing the pricing power of the three innovator companies that still hold more than 60% of the global insulin market. The biosimilar insulin market also offers room for long-acting products, contract manufacturing, and localized production, which keeps new entrants interested.
Competition is now visible in high-income markets as well. In January 2026, the non-profit drugmaker Civica began selling insulin glargine in the United States, manufactured by Biocon Biologics and carrying a recommended consumer price of no more than US$55 for a box of five pens. Glargine is an analogue, yet the move shows how transparent, low-cost supply is changing buyer expectations across the whole insulin category. For human insulin suppliers, price alone will not protect volume, and reliability of supply will count just as much.
Value growth remains slower than volume growth. Clinical guidelines in developed markets often favor analogues for their predictable action. Affordability policies such as the US$35 monthly cap on insulin co-payments for Medicare beneficiaries limit price increases. This is why suppliers are looking beyond the molecule itself to find new ways to differentiate.
Improved Quality Assurance is Opening Public Procurement to More Suppliers
Procurement agencies need confidence in quality before they buy from new manufacturers, and regulatory support is starting to provide it. In March 2026, the World Health Organization expanded its insulin master file procedure, first launched in 2023 for human insulin, to cover insulin analogues as well. WHO noted that human insulin remains the most affordable option, while leading suppliers are phasing out old insulin products to focus on new and profitable treatments.
A simple route to prequalification allows more producers to compete for public purchasing. This strengthens supply security and keeps price competition active. For established players, it raises the importance of consistent quality and dependable cold-chain distribution.
Pens and Connected Devices Are Adding Value to a Low-Cost Therapy
Delivery has become the main way to differentiate a medicine whose molecule is no longer new. Insulin pens account for about 55% of delivery device share in the global human insulin market. Also, the insulin pens market was valued at US$8.4 Bn in 2025 and is expected to reach US$14.6 Bn by 2032, surging at a CAGR of 8.2% between 2025 and 2032. Better dosing accuracy, easy handling, and strong adherence among elderly patients explain why pens are growing faster than the insulin they deliver.
Connected devices take this further. In January 2026, Medtronic received the U.S. FDA clearance for the MiniMed Go system, which links its InPen smart insulin pen with a glucose sensor made by Abbott through a single app. The system offers a dose calculator, missed-dose alerts, and guidance when a dose is missed or miscalculated. In February 2026, Medtronic started the European launch of the same system with its Simplera sensor.
These launches show how pen data and glucose readings are being merged into one decision-support layer, a direction also reflected in the continuous glucose monitoring systems market. As large data sets build up, machine learning is expected to refine dose recommendations over time. For human insulin makers, bundling their formulations with such networks is a practical way to move from commodity supply to a managed therapy.
Needle-Free Options Are Expanding Patient Choice Beyond Injections
Innovation is reaching the route of administration. In January 2026, MannKind received FDA approval for an updated Afrezza label, which covers inhaled insulin human and adds clear starting-dose guidance for adults switching from multiple daily injections or pump mealtime therapy. Transparent conversion guidance helps clinicians adopt inhaled therapy with confidence, and it shows that human insulin is still being rethought for patients who want alternatives to injections.
Companies That Pair Affordable Supply with Smart Delivery Are Best Placed to Gain
The next phase of growth will likely favor companies that combine low-cost supply with a better patient experience. Novo Nordisk, Sanofi, and Eli Lilly are predicted to extend their connected pen portfolios and regional manufacturing partnerships to defend volume while adding service value.
Biocon, Wockhardt, Tonghua Dongbao, and Gan & Lee are projected to build on their scale by expanding premixed and long-acting offerings in price-sensitive markets and by pursuing prequalification for public tenders. As diabetes care becomes more data-driven, the winners in the human insulin market are likely to be those that treat insulin as part of a complete therapy system rather than a stand-alone product.
